Search
Nogapendekin alfa
go.drugbank.com/drugs/DB18740ApprovedInvestigational[L50592] This combination product was approved by the FDA on April 22, 2024, for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without … [L50627] Non-muscle invasive bladder cancer (NMIBC), which accounts for 75% of all bladder tumours, is commonly treated with transurethral resection of the bladder tumour and Bacillus Calmette-Guérin (
Lotilaner
go.drugbank.com/drugs/DB17992ApprovedInvestigationalVet approved[A260741] On July 25, 2023, lotilaner was approved by the FDA for the treatment of Demodex blepharitis, making it the first and only approved therapeutic for this condition.[L47551] … [L47546] Lotilaner has largely been used for veterinary uses as an antiparasitic agent to treat flea and tick infestations in animals.
Synonyms: 2-thiophenecarboxamide, 5-((5s)-4,5-dihydro-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-3-isoxazolyl)-3-methyl-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-, 3-methyi-n-(2-oxo-2-((2,2,2-trifluoroethyl)amino)ethyl)-5-((55)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl)thiophene-2-carboxamideNaltrexone
go.drugbank.com/drugs/DB00704ApprovedInvestigationalVet approvedDerivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeSynonyms: N-Cyclopropylmethylnoroxymorphone, N-Cyclopropylmethyl-14-hydroxydihydromorphinoneLanolin alcohols
go.drugbank.com/drugs/DB14181ApprovedLanolin alcohols are a complex combination of organic alcohols obtained by the hydrolysis of lanolin. … It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.
Tixocortol
go.drugbank.com/drugs/DB09091ApprovedWithdrawnTixocortol is a 21-thiol derivative of hydrocortisone classified as a class A corticosteroid. It is a synthetic steroid with topical anti-inflammatory properties without the systemic glucocorticoid and mineralocorticoid activities and to...
Delamanid
go.drugbank.com/drugs/DB11637ApprovedInvestigationalDelamanid is approved by the EMA and is marketed under the trade name Deltyba as oral tablets. It is marketed by Otsuka Pharmaceutical Co., Ltd (Tokyo, Japan). … Spontaneous resistance to delamanid was observed during treatment, where mutation in one of the 5 F420 coenzymes responsible for bioactivation of delamanid contributes to this effect [L1407].
Nipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigational[L64042] It is administered by intravenous infusion.[L64042] Nipocalimab-aahu was first approved by the FDA in April 2025 for generalized myasthenia gravis. … Nipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases.
Sebelipase alfa
go.drugbank.com/drugs/DB11563ApprovedInvestigationalIt was first approved by both the FDA and EMA in 2015 and is marketed under the brand name Kanuma (Alexion Pharmaceuticals).[L39337,L39342] … This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction.
Safinamide
go.drugbank.com/drugs/DB06654ApprovedInvestigationalIt was approved in Europe in February 2015, and in the United States on March 21, 2017.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeChlorotoxin I-131
go.drugbank.com/drugs/DB05462InvestigationalChlorotoxin is a small 36-amino-acid peptide that selectively binds to glioma cells but not normal brain parenchyma. … The selective effects of Chlorotoxin I-131 are regulated by its action on MMP2 receptors.